Trials / Completed
CompletedNCT04814108
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Detailed description
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azenosertib | Azenosertib is an investigational drug. |
Timeline
- Start date
- 2021-07-28
- Primary completion
- 2025-10-22
- Completion
- 2025-10-22
- First posted
- 2021-03-24
- Last updated
- 2026-03-18
Locations
56 sites across 4 countries: United States, Australia, Canada, Georgia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04814108. Inclusion in this directory is not an endorsement.